Optimer Pharma (OPTR) Stock Slips on Numerous Analyst Downgrades
More News related to OPTR
- Optimer Pharmaceuticals Appoints Robert L. Zerbe, M.D. to its Board of Directors
- Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
- Oppenheimer Upgrades Optimer Pharmaceuticals (OPTR) to Outperform
- Morning Movers 11/12: NLST, HPJ, COMS, AMD, CAAS Higher; TRMS, NWPX, ATRN, BRCD, CDTI, GMCR Lower
- Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clostridium difficile Infection
More News related to Downgrades
- Merriman Curhan Ford Downgrades Smith & Wesson Holding (SWHC) to Neutral; Near-Term Outlook Clouded
- Wells Fargo Downgrades Take-Two Interactive (TTWO) to Market Perform; Weak Retail Environment
- Wells Fargo Downgrades Endo Pharmaceuticals (ENDP) to Market Perform; Pipeline Delays Cause Concern, Add Pressure
- Piper Jaffray Downgrades Endo Pharmaceuticals (ENDP) to Neutral; Moving to Sidelines on Aveed Concerns
- Piper Jaffray Downgrades Take-Two Interactive (TTWO) to Neutral; Slashes Estimates & PT on Weak Retail Environment
Shares of Optimer Pharmaceuticals (Nasdaq: OPTR) have fallen sharply today following news early yesterday that the results from a Phase 3 trial of fidaxomicin were presented at the 19th annual European Congress of Clinical Methodology and Infectious Diseases. The stock most recently traded at $10.83, down more than 7% from Optimer's close on Friday of last week.
Also creating downside today, the stock was downgraded this morning by analysts at Needham & Co., Ladenburg Thalmann and JMP Securities. Needham cut the stock from Buy to Hold, while Ladenburg moved the stock from Buy to Neutral. JMP downgraded Optimer from Market Outperform to Market Perform.
To see all the analyst calls on shares of Optimer, click here or go to http://www.streetinsider.com/stock_lookup_news.php?q=optr&type=analyst.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
